Societe Generale set a €117.00 ($139.29) target price on Bayer (FRA:BAYN) in a research report sent to investors on Tuesday, November 14th. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other equities analysts have also recently issued reports on the company. DZ Bank restated a buy rating on shares of Bayer in a report on Tuesday, November 14th. Jefferies Group set a €137.00 ($163.10) target price on Bayer and gave the stock a buy rating in a report on Tuesday, November 14th. Goldman Sachs Group set a €125.00 ($148.81) target price on Bayer and gave the stock a buy rating in a report on Tuesday, November 7th. Barclays set a €105.00 ($125.00) target price on Bayer and gave the stock a sell rating in a report on Monday, November 6th. Finally, UBS set a €125.00 ($148.81) price target on Bayer and gave the stock a buy rating in a research report on Monday, November 6th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of €122.43 ($145.75).
Bayer (BAYN) traded down €0.85 ($1.01) on Tuesday, reaching €106.80 ($127.14). The company had a trading volume of 5,228 shares. Bayer has a one year low of €86.06 ($102.45) and a one year high of €123.82 ($147.40).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with our FREE daily email newsletter.